Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04250246
Title A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)
Acronym NIBIT-ML1
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Italian Network for Tumor Biotherapy Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Center for Immuno-Oncology, University Hospital of Siena Siena 53100 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field